A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Recruiting

Phase 3

Linvoseltamab vs. DaratumumabA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07393282

Conditions

High Risk Smoldering Multiple Myeloma (HR-SMM)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Linvoseltamab

Daratumumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-27. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-06-10.